2024 World Conference on Lung Cancer (WCLC) - Posters-P4.11E.12 First Line Camrelizumab for Brain Metastases of NSCLC (CTONG 2003): A Randomized Controlled Trial

Pdf Summary

The CTONG 2003 trial is a landmark randomized controlled trial aimed at evaluating the efficacy and safety of camrelizumab, an anti-PD-1 antibody, in combination with chemotherapy, for patients with brain metastases from non-small-cell lung cancer (BM-NSCLC) without driver gene alterations. This trial, conducted across 15 sites in China, represents a significant step forward as it prospectively evaluates the impact of immunotherapy as a first-line treatment for this condition.<br /><br />A total of 60 participants were enrolled between May 2021 and July 2023, with 32 receiving camrelizumab and 28 receiving a placebo. The trial was prematurely closed due to evolving treatment standards, which rendered placebo infeasible. Despite its early termination, the study revealed that camrelizumab tends to improve progression-free survival (PFS) and intracranial PFS (iPFS). Specifically, the median iPFS was 12.7 months for the camrelizumab group versus 8.4 months for the placebo group, and the median PFS was 9.7 months compared to 6.7 months, respectively.<br /><br />In terms of safety, 68.8% of patients in the camrelizumab group experienced significant treatment-related adverse events, mainly anemia and neutropenia, compared to 60.7% in the placebo group. Notably, there was one case of a grade 5 treatment-related adverse event in the camrelizumab cohort.<br /><br />The camrelizumab group also exhibited a higher intracranial objective response rate (iORR) at 56.3% compared to 42.9% for the placebo group, demonstrating more robust tumor responses. Overall survival also showed a positive trend in favor of camrelizumab.<br /><br />Conclusively, the trial suggests that camrelizumab may offer an effective treatment option, with manageable side effects, for patients with BM-NSCLC, warranting further research to confirm these preliminary findings.

Asset Subtitle

Yang-Si Li

Meta Tag

Speaker Yang-Si Li

Topic Metastatic NSCLC – Immunotherapy

Keywords

CTONG 2003 trial

camrelizumab

anti-PD-1 antibody

brain metastases

non-small-cell lung cancer

randomized controlled trial

progression-free survival

intracranial objective response rate

treatment-related adverse events

immunotherapy